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Introduction 
 Huntington’s disease (HD) is a progressive, fatal, neurodegenerative disorder caused 
by an abnormal expansion of a CAG repeat sequence in the gene encoding the protein 
huntingtin (HTT) on chromosome 41. The cellular functions of HTT are still not completely 
understood2-5.  Most available evidence suggests that HD arises predominantly from gain of a 
toxic function of mutant HTT6, 7, that results in myriad molecular and pathophysiological 
features, including mitochondrial dysfunction, intracellular trafficking defects, abnormalities of 
protein folding and/or processing8-10. The disease is transmitted as a late onset autosomal 
dominant trait with age-dependent penetrance11. HD affects approximately 4–8 individuals per 
100,00012 and typically presents between 35 and 45 years of age, with an average survival of 
15–25 years after disease onset13. Individuals at risk of inheriting the expanded CAG nucleotide 
can be identified before clinical onset by predictive genetic testing. Pathologic studies show a 
massive striatal neuronal cell death with up to 95% loss of GABAergic medium spiny projection 
neurons, which project to the globus pallidus and the substantia nigra, whereas large 
interneurons are selectively spared14, 15. However, neurodegeneration is more widespread, 
even long before the disease onset16, 17, and includes a range of cortical and subcortical 
structures as well as a global brain shrinkage.  
 Clinical features of HD include progressive motor dysfunction, cognitive decline, and 
psychiatric disturbance4, 18. Motor signs include involuntary movements (chorea), that tipically 
worsens during walking, concentration and stress. With disease evolution chorea impairs gait 
balance and voluntary movements. The motor score of the Unified Huntington’s Disease 
Rating Scale (UHDMRS) includes all motor systems affected and is a useful tool to assess 
patients and disease progression1, 19. A wide range of disorders of mental function and 
behavior occur at any time during the disease20. Cognitive changes are always present and can 
be present early in the disease21-24. The diagnosis is made on clinical examination, based on the 
5 
 
combination of motor, behavioural and cognitive symptoms in the setting of a family history of 
the disease25. A DNA test showing abnormal CAG expansion in the HTT gene can be used to 
confirm the diagnosis. Atrophy of the caudate nucleus on cerebral magnetic resonance 
imaging (MRI) supports the diagnosis. Although no curative treatment is available today, 
symptomatic treatment of chorea may be beneficial in some individuals, as it may have a 
favorable effect on motor function and quality of life26, 27.  
 
  Sleep disturbances are frequent in HD patients. In a self or carer-completion 
questionnaire, 87.8% of patients reported sleep-related problems, rated as important by 
61.7%; these disorders consisted mainly in restless limb movements, periodic jerks, nocturnal 
awakenings, daytime sleepiness and early awakening28. Disturbed sleep was a prominent 
feature of the advanced disease, substantially impairing the quality of life of both patients and 
caregivers28. Recently, Goodman et al29 reported asymptomatic sleep changes since early 
stages, often long before motor disturbances. In this study, subjects remained significantly 
longer in bed,  spent more time awake, had a marked reduction of deep sleep and rapid eye 
movement (REM), but none reported excessive daytime sleepiness (EDS). Moreover, patients 
had alterations in rest-activity cycles similar to those described in more advanced stages of the 
disease, suggesting that sleep abnormalities start early in the disease course and might 
represent crucial therapeutic target.  
  
 Polysomnography and actigraphy in small groups of HD patients have documented an 
increased sleep onset latency30, sleep fragmentation and frequent nocturnal awakenings, 
reduced sleep efficiency, delayed and shortened REM sleep, increased periodic leg 
movements, as well as circadian rhythm disturbances31-39. Moreover, apart from affecting 
alertness, attention, memory and executive control, lack of sleep may also be considered as a 
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risk factor for developing depression40. However, sleep alterations as well as their association 
with other symptoms and signs of the disease have not been systematically studied in large 
groups of HD patients. 
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Aims of the study 
The aims of the study were: 
 
1) the primary aim of the study was to objectively evaluate sleep features in a large, single-
center, population of HD patients by means of nocturnal, laboratory based video-
polysomnography (V-PSG), and to correlate PSG findings with clinical parameters; 
 
2) a secondary aim was to evaluate subjective sleep-related symptoms, and to test the clinical 
reliability of subjective sleep evaluation, based on a battery of sleep and psychometric 
questionnaires, by comparing the results with those obtained with the gold standard 
diagnostic tool, namely V-PSG; 
 
3) finally, we decided to evaluate the EEG modifications in HD patients during the sleep-wake 
cycle, by means of the exact LOw REsolution Tomography (eLORETA) software and to evaluate 
correlations indexes between EEG power spectra and clinical features. 
  
8 
 
Patients and Methods 
Patients 
 A cohort of 30 consecutive adult HD patients was enrolled, 16 women and 14 men, 
mean age was 57.3±12.2 years (range: 41-80 years). Patients were recruited at the Movement 
Disorders Center of the Catholic University in Rome from February to June 2014. The inclusion 
criteria were age>18 years, and diagnosis of HD. Diagnosis of HD was based, according to the 
established criteria41, on clinical criteria and confirmed by genetic testing in 21/30 (70%). The  
9 patients who refused to undergo genetic testing were definitely clinically affected by HD and 
had a familiar history of HD with at least one family member genetically confirmed. Fifteen 
patients were taking tetrabenazine, 18 were on neuroleptic treatment, 15 assumed 
antiepileptic drugs (AEDs) as mood stabilizers (prevalently valproic acid). Most patients (23/30) 
were assuming more than one drug.  
       
Treatment 
  Age Sex Neck BMI 
Disease 
duration 
UHDMRS CAG TBZ NLP MTD Li BZD AEDs ADP 
1 45 F 32,0 20,57 4 58 47 yes no no yes no no no 
2 63 M 34,5 17,24 
 
63 
 
no yes no yes yes no no 
3 60 F 31,0 19,98 1 12 40 no no yes no no no no 
4 80 F 32,0 17,19 8 63 40 yes yes no no yes no yes 
5 40 F 31,0 19,56 4 27 57 no no yes no no no no 
6 60 F 35,0 15,43 14 103 45 yes no no no no yes no 
7 49 M 39,0 22,89 
   
no no no no no no no 
8 59 F 34,0 27,55 18 57 45 no yes no no yes yes no 
9 41 F 31,0 19,53 4 19 48 no no no no no yes no 
10 78 M 37,5 19,84 10 69 42 no no no no no yes no 
11 71 M 35,6 22,41 10 49 43 no yes yes no no no no 
12 43 M 43,0 20,40 5 88 
 
yes yes no no no yes no 
13 53 F 32,0 17,58 7 78 
 
yes yes yes no yes yes no 
14 45 F 32,0 21,97 14 80 
 
no yes yes yes no yes no 
15 50 M 45,0 23,99 12 63 46 yes yes yes no yes yes no 
16 52 M 37,0 21,51 12 36 
 
no yes yes no no no no 
17 75 F 34,0 24,65 11 36 40 yes no no no no no no 
18 71 F 34,0 20,90 10 50 
 
no yes yes no no yes no 
19 68 F 33,0 32,87 6 39 41 no yes no no no yes no 
20 57 F 38,0 22,03 10 75 43 yes yes yes no yes no yes 
21 43 M 40,0 26,81 6 40 
 
no no yes no no no no 
22 61 F 37,0 28,30 8 61 44 yes no yes no no no no 
23 48 F 33,0 15,43 13 89 
 
yes yes no no no yes yes 
24 56 M 40,5 24,49 8 31 44 no yes no no yes yes yes 
25 43 M 38,5 23,27 12 68 52 yes yes yes yes no yes no 
26 74 F 37,0 22,48 17 75 42 yes yes yes no no no no 
27 78 M 40,0 21,13 18 61 43 yes no yes no no no no 
28 51 M 40,0 25,88 6 20 43 no yes no yes no yes no 
29 53 M 39,0 25,83 4 26 43 yes no no no no no no 
30 52 M 34,0 16,98 12 75 43 yes yes no no no yes no 
Mean 57,30 
 
35,99 21,96 9,43 55,55 44,33 
       
SD 12,24 
 
3,75 4,01 4,49 23,43 4,08 
       
Total 
 
14M, 16F 
     
15 18 14 5 7 15 3,00 
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 In the EEG spectral analysis, a subgroup of 23 consecutive patients (belonging to the 
same cohort) was enrolled, including 14 women and 9 men, mean age was 57.0±12.4 years 
(range: 40-80 years)42.  
 
  Age Gender 
Disease 
duration 
UHDMRS 
CAG 
repeats 
1 60 F 1 12 40 
2 80 F 8 63 40 
3 40 F 4 27 57 
4 60 F 14 103 45 
5 49 M 4 25 
 
6 59 F 18 57 45 
7 41 F 4 19 48 
8 43 M 5 88 
 
9 53 F 7 78 
 
10 45 F 14 80 
 
11 50 M 12 63 46 
12 75 F 11 36 40 
13 71 F 10 50 
 
14 68 F 6 39 41 
15 57 F 10 75 43 
16 43 M 6 40 
 
17 61 F 8 61 44 
18 56 M 8 31 44 
19 43 M 12 68 52 
20 74 F 17 75 42 
21 78 M 18 61 43 
22 51 M 6 20 43 
23 53 M 4 26 43 
Mean 56,96 
 
9,00 52,04 44,47 
SD 12,43 
 
4,83 25,10 4,45 
Total 
 
9M, 
14F    
 
 
Control groups 
Sleep scores and V-PSG findings in HD patients were compared with a control group of 
30 healthy subjects matched for age and sex (14 men, 16 women, mean age 56.5±11.8 years, 
range 38 – 76).  
In the EEG study, power spectra of HD patients were compared with those of a control 
group of 23 healthy subjects, matched for age and sex: 14 women and 9 men, mean age was 
58.2±14.6  years (range: 38-81 years)42. Control subjects were healthy volunteers, without 
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subjective complaint of sleep disorders or diurnal symptoms consistent with sleep disruption. 
Controls underwent a full medical and neurological evaluation, and a hypnological interview to 
rule out present or previous history of sleep disorders. No subject in this group was taking 
Central Nervous System active drugs at the time of the study.  
 
The study was approved by the local Ethical committee. All patients and control 
subjects were fully informed and all gave a written consent to participate.  
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Methods 
Clinical and neurologic evaluation 
 All Patients underwent a medical and neurological examination, including measures of 
weight, height, body mass index (BMI) and neck circumference. The following clinical features 
were evaluated: disease duration, clinical severity (measured by means of the UHDMRS43), 
disease burden (calculated by the formula: CAG-35.5 X age44), number of CAG repeats, 
pharmacological treatments. In the present study the motor and behavioral symptoms did not 
allow the withdrawal of pharmacological therapies, which were kept unmodified during the 
evaluation period. 
 
Subjective sleep evaluation 
 Sleep anamnesis was collected and questionnaires were administered by a sleep 
specialist. Subjective evaluation of sleep quality was performed by the validated Italian version 
of the Pittsburgh Sleep Quality Index (PSQI)45. A global score ≥5 was considered an indicator of 
poor sleep quality46. Sleep quality was also assessed by means of a specific questionnaire 
validated for HD patients (HDQ)29. This questionnaire evaluates 4 aspects of sleep: sleep 
quality, motor activity, abnormal motor behavior during sleep and other sleep disorders. Out 
of a total score of 19 points, scores of 0–3 represent the ‘normal’ range, while scores of 4–6 
reflect ‘mild’ and scores of 7 and above indicate a ‘significant’ sleep disturbance which may 
merit further investigation and/or treatment.29  
 For the evaluation of EDS, two scales were used: the validated Italian version of the 
Epworth Sleepiness Scale (ESS)47, and the Bologna questionnaire. The ESS is a validated, widely 
adopted questionnaire for the evaluation of sleepiness; the cut-off score for defining EDS was 
ESS=9. The Bologna questionnaire is a validated questionnaire which contains questions 
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concerning concepts such as “tiredness”, “resistible sleepiness”, “irresistible sleepiness” and 
“sudden sleep attacks”; the questionnaire divides patients in two groups, with “high risk” or 
“low risk” of EDS.48 
 An evaluation of the symptoms and clinical signs predictors of Obstructive Sleep Apnea 
syndrome (OSAS) was performed by means of the Berlin Questionnaire49. This evaluation 
included the measure of neck circumference, BMI, presence of habitual snoring, nocturia, 
morning headache, arterial hypertension, and apneas reported by the bed-partner. For 
diagnosis of RLS the validated four-item RLS criteria was used50. Fulfillment of all four criteria 
was required for diagnosis. The IRLLSG scale was administered to patients with positive RLS 
screening, in order to measure the severity of the disturbance. In order to evaluate the 
presence of REM sleep Behavior Disorder (RBD), the RBD questionnaire51 was used.  
   
Psychological functioning measures 
 The psychometric evaluation included the following scales: the Zung Anxiety Scale (SAS 
#54)52, the short form of the Beck’s Depression Inventory (BDI-SF)53, the Maudsley’s Obsessive 
Compulsive Inventory (MOCI54). The SAS #54 is a method of measuring levels of anxiety in 
patients who have anxiety-related symptoms. It uses a 4-point Likert-type scale, ranging  from 
1 to 4. The SAS contains 20 items with 15 increasing anxiety level questions and 5 items 
reverse scored. High scores correspond to higher levels of anxiety. The BDI-SF is a 13-item 
validated self-report instrument measuring characteristic attitudes and symptoms of 
depression over the previous two weeks. Scores >9 indicate mild to severe depression. The 
MOCI is a questionnaire with true-false format developed for evaluating the type of obsessive-
compulsive symptoms and discriminating obsessive patients from other neurotic patients and 
from nonclinical people. The total score ranges between 0 (absence of symptoms) and 34 
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(maximum presence of symptoms). The MOCI has four subscales which measure the following 
traits: Checking, Cleaning, Slowness, and Doubting. 
 
Objective sleep evaluation 
Video-Polysomnography 
 Full-night, attended, laboratory-based V-PSGs were recorded in acclimatized, sound-
proof rooms. Time of PSG recording was fixed (between 11 pm and 7 am). Recording montage 
included  EEG leads applied to following locations: Fp1, Fp2, F3, Fz, F4, F7, F8, C3, Cz, C4, T3, 
T4, T5, T6, P3, Pz, P4, O1, O2; reference electrodes applied to the left (A1) and right (A2) 
mastoids; 2 EOG electrodes applied to the outer ocular cantus and referred to the contra-
lateral mastoid, surface EMG of sub-mental and intercostal muscles, right and left anterior 
tibialis, right and left extensor communis carpi, airflow measured by thermocouple 
transducers, thoracic and abdominal effort, EKG and peripheral hemoglobin saturation 
measured by a sensor placed on a finger. Continuous audio and video recording was 
performed by means of infra-red cameras. Sleep recordings were analyzed on computer 
monitor, and sleep stages were visually classified according to the criteria of the American 
Academy of Sleep Medicine55. Sleep stage percentages were calculated related to Total Sleep 
Time (TST). The arousal indexes56 (number of arousals per hour) were calculated for total 
sleep, NREM and REM stages. 
 The scoring of sleep-related respiratory events was performed visually, according to 
the criteria established by the AASM (2007)57. The analysis of the SpO2 parameters was made 
with a dedicated software (Rembrandt SleepView-Medcare©). Oxygen desaturation events 
were defined as a fall in SpO2≥3%. In the analysis of saturation, the following parameters were 
considered: baseline SpO2, lowest SpO2, Oxygen Desaturation Indexes (ODI) in total sleep, in 
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NREM and in REM. OSA was defined by the presence of an Apnea-Hypopnea Index (AHI) >5 
events per hour of sleep (including obstructive and mixed events); Central Sleep Apnea (CSA) 
was defined by the presence of a Central Apnea-Hypopnea Index (CAHI) >5 events per hour of 
sleep. Periodic Limb Movements in Wake and Sleep (PLMW – PLMS) were scored according to 
established criteria58, and PLM indexes were calculated for upper and lower limbs, and for 
wake, the entire sleep period, NREM and REM sleep. The cut-off value for abnormal PLM 
indexes during wake and sleep was 15 events/hour58. Additionally, the number of inter-
movement intervals that were 10–90s long and all in sequences of at least 3, was divided by 
the total number of intervals to yield the periodicity index (PI); this index can vary between 0 
(absence of periodicity, with none of the intervals having a length between 10 and 90s) to 1 
(complete periodicity, with all intervals having a length between 10 and 90s)59. 
 
EEG 
 Continuous EEG recordings were performed during wake (before sleep) and during 
sleep. Periods of wake were detected visually, on the basis of the EEG trace and the 
simultaneous video recording. Epochs of EEG slowing, consistent with drowsiness, were 
detected visually and excluded from analysis. EEG was recorded by means of a Micromed 
System Plus digital EEGgraph (Micromed© S.p.A., Mogliano Veneto, TV, Italy). EEG montage 
included 19 standard scalp leads positioned according to the 10 - 20 system (recording sites: 
Fp1, Fp2, F7, F3, Fz, F4, F8, T3, C3, Cz, C4, T4, T5, P3, Pz, P4, T6, O1, O2). The reference 
electrodes were placed on the linked mastoids. Impedances were kept below 5KΩ before 
starting the recording and checked again at the end. In particular, impedances of the mastoids 
reference electrodes were checked to be identical. This electrode montage is considered as an 
adequate EEG spatial sampling for the estimation of cortical sources of eyes closed resting 
state EEG rhythms with the eLORETA software, since these rhythms are widely represented 
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across all human cerebral cortex in contrast to the circumscribed functional topography of 
event-related EEG changes (especially at high frequencies) in response to specific sensory or 
motor events60. Therefore, eyes closed resting state EEG rhythms can be properly sampled 
with a relatively low amount of electrodes, as opposed to the higher spatial sampling required 
to take into account to the detailed functional topography of event-related EEG activity. This 
relatively low-spatial sampling of EEG rhythms is in line with the fact that LORETA solutions are 
intrinsically maximally smoothed at source space, due to its regularization procedure60, 61. 
Sampling frequency was 256 Hz; analogic to digital conversion was made at 16 bit; pre-
-frequency pre-filters were set at 0.15 Hz. 
The following bandpass filters were used: HFF = 0.2 Hz; LFF = 128 Hz. The line noise (in Italy: 
50Hz) was removed by using a 50Hz notch filter. In the off-line analysis, rejection of artifacts 
(eye movements, blinks, muscular activations, respiratory or movement artifacts) was 
performed visually on the raw EEG trace, by posing a marker at the onset of the artifact signal 
and a further marker at the end of the artifact. Successively, the artifact segment (that is, the 
EEG signal interval included between the two markers) was deleted, and this cancellation 
involved all the EEG traces acquired within that interval. In this way, all the EEG intervals 
characterized by the presence of artifacts were excluded from the analysis. After artifact 
rejection, the remaining EEG intervals were exported into American Standard Code for 
Information Interchange (ASCII) files, and imported into the eLORETA software. We analyzed 
segments of EEG recorded in wake and during NREM and REM. The average length of each EEG 
segment analyzed were the following: wake=371±23 sec.; NREM=418±12 sec.; REM=379±34 
sec.. Detailed method of PSG recording have been described previously62. All EEG analysis were 
performed by means of the eLORETA software63.  
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eLORETA 
For the estimation of cortical sources of EEG rhythms was used LORETA software as 
provided at http://www.unizh.ch/keyinst/NewLORETA/LORETA01.htm63. LORETA belongs to a 
family of linear inverse solution procedures modeling 3D distributions of EEG sources61.  
eLORETA computes 3D linear solutions for the EEG inverse problem within a three-shell 
spherical head model including scalp, skull, and brain compartments. LORETA solutions consist 
of voxel current density values able to predict EEG spectral power density at scalp electrodes. 
eLORETA is a reference-free method of EEG analysis, which allows to obtain the same source 
distribution for EEG data independently from the reference electrode. Estimated cortical 
sources of scalp EEG voltages are expected to reflect the synchronous synaptic neural currents 
of the pyramidal cortical neurons, which are associated to local field potentials.  LORETA 
computes 3D linear solutions (LORETA solutions) for the EEG inverse problem within a three-
shell spherical head model including scalp, skull, and brain compartments. The brain 
compartment is restricted to the cortical gray matter/hippocampus of a head model co-
registered to the Talairach probability brain atlas and digitized at the Brain Imaging Center of 
the Montreal Neurological Institute64. eLORETA images represent the standardized electrical 
activity at each of 6239 cortical voxels (spatial resolution 5 mm) in Montreal Neurological 
Institute space.  LORETA computes relative currents for z, x, and y components of any dipole. 
 
Frequency analysis 
EEG frequency analysis was performed by means of Fast Fourier Transform algorithm, 
with a 2 seconds interval on the EEG signal, in all scalp locations. The following frequency 
bands were considered: delta (0.5–4 Hz); theta (4.5–7.5 Hz); alpha (8–13.5 Hz); beta (14-30 
Hz); gamma (30.5–60 Hz. For frequency analysis, monopolar EEG traces (each electrode 
referred to joint mastoids) were used. Topographic sources of EEG activities were determined 
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using the eLORETA software. The eLORETA software computes the current distribution 
throughout the brain volume. In order to find a solution for the 3-dimensional distribution of 
the EEG signal, the eLORETA method assumes that neighbouring neurons are simultaneously 
and synchronously activated. This assumption rests on evidence from single cell recordings in 
the brain that shows strong synchronization of adjacent neurons65, 66. The computational task 
is to select the smoothest of all possible 3-dimensional current distributions, a common 
procedure in signal processing67, 68. The result is a true 3-dimensional tomography, in which the 
localization of brain signals is preserved with a low amount of dispersion63. 
 
Statistical analysis 
 PSG data obtained in the patient group were compared to those obtained from 
controls. All sleep parameters and PSG measures were compared in these two groups by 
means of a non-parametric test (Mann-Whitney U-test). The threshold for significance was 
p=0.05. In case of multiples comparison, in order to avoid family-wise type I errors, a formal 
Bonferroni correction was applied to each family of comparisons, by dividing the limit of 
significance by the number of comparisons (for the ODI, 3 comparisons were made, in the 
conditions ‘sleep’, ‘NREM’ and ‘REM’, therefore the threshold level for significance was 
p=0.05/3=0.017; for the PLM indexes, 4 comparisons were made, in the conditions ‘wake’, 
‘sleep’, ‘NREM’ and ‘REM’, therefore the threshold level for significance was p=0.05/4=0.0125). 
Moreover, within the HD group, we calculated the correlation indexes between sleep 
parameters and the clinical findings (UHDMRS, CAG repeats, disease duration). These 
correlations were evaluated by means of the Spearman correlation index: the critical value of 
the Spearman’s ranked correlation coefficient was ρ=0.362, corresponding to a significance 
level p<0.05. Correlations were controlled for age differences. 
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  The analysis of subjective sleep evaluation was performed in three successive steps: in 
the first step, we compared the results of the sleep evaluations performed by means of the 
different scales utilized, in order to evaluate the degree of agreement. In particular, we 
compared the measures of daytime sleepiness obtained with ESS with those of the Bologna Q; 
and we compared the measures of sleep quality obtained with PSQI vs HDQ. We measured the 
number of patients in which the results of the scales gave concordant or discordant results; 
'concordant' were considered those cases in which both scales showed results above or below 
the cut-off. As for the HDQ, two different cut-off were considered: >3 (‘mild sleep disorder’) 
and >7 (‘significant sleep disorder’)29. Questionnaire results were further compared by an 
individual analysis to calculate the kappa statistic, which accounts for the amount of 
agreement expected. 
 In the second step, we compared the scores of sleep questionnaires with PSG data. For 
the PSQI and the HDQ, comparison were made with sleep efficiency index (SEI). 'Poor sleep' in 
subjective evaluation was defined as PSQI score ≥5 and HDQ≥3 or HDQ≥7; in objective 
evaluation 'poor sleep' was defined as SEI<82.7%, calculated as the mean-2 DS of a population 
of adult healthy controls recorded as normative data of our sleep laboratory. Moreover, to 
evaluate in deeper detail the sleep quality results, the sub-items of the PSQI scale were 
compared to PSG findings; in particular, the component C2 was compared to sleep latency (SL), 
C3 to Total Sleep Time (TST), C4 to SEI and C5 to the number of awakenings lasting > 1 minute 
(Aw). Again, the cut-off values were defined as the mean ± 2 DS of our controls. The following 
cut-off for PSG values were used: SL>48.8 minutes; TST<303.3 minutes; SEI<82.7%; Aw >7.9. 
For all  these parameters we measured the kappa statistic; moreover, we computed the 
accuracy, sensitivity and specificity of each measure69. For these, we used the definitions set 
forth by Tilmanne et al. (2009)70 to calculate accuracy, sensitivity and specificity70. When 
compared with PSG, a true positive (TP) indicates that the questionnaire identifies the disorder 
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correctly, a true negative (TN) indicates that the questionnaire identifies absence of 
disturbance, a false negative (FN) indicates that the scale misidentifies the disorder, and a false 
positive (FP) indicates that the scale identifies a unconsistant disorder. Accuracy is then 
defined as (TP + TN)/(TP + TN + FN + FP) and represents the agreement rate between PSG and 
the scale; sensitivity is defined as TP/(TP + FN) and represents the percentage of disorders 
identified correctly; and specificity is defined as TN/(TN + FP) and represents the percentage of 
subjects correctly identified as good sleepers. Finally, correlation were analyzed between sleep 
questionnaires (ESS, PSQI, HD, RBD), and clinical data and psychometric scores (age, disease 
duration, UHMDRS,  number of CAG repeats, BDI, Zung-A and MOCI). These correlations were 
evaluated by means of the Spearman correlation index: the critical value of the Spearman’s 
ranked correlation coefficient was (28)=0.375, corresponding to a significance level p<0.05.  
In the EEG study, power spectra were compared among conditions, for each frequency 
band. The conditions analyzed were three: wake, NREM, REM. All comparisons were 
performed by using the statistical non-parametric mapping methodology supplied by the 
LORETA software 71. This methodology is based on the Fisher’s permutation test: a subset of 
non-parametric statistics. In particular, this is a type of statistical significance test in which the 
distribution of the test statistic under the null hypothesis is obtained by calculating all possible 
values of the test statistic under rearrangements of the labels on the observed data points. 
Correction of significance for multiple testing was computed for the two comparisons between 
conditions for each frequency band: for the correction, we applied the non-parametric 
randomization procedure available in the LORETA program package 71. T-level threshold were 
computed by the statistical software implemented in the LORETA, which correspond to 
threshold of statistical significance (p<0.01) for details see, 72, 73. 
 Finally, Spearman's rho correlation coefficients were computed  as measures of 
correlation between EEG power spectra (in the Broadman Areas 4, bilaterally) and clinical 
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features (age, BMI, disease duration, disease burden, CAG repeats); the critical value of the 
Spearman' rho coefficient was (21)=0.41, corresponding to p=0.05. All statistics were 
performed by means of the SYSTAT 12 software version 12.02.00 for Windows® (copyright 
SYSTAT® Software Inc. 2007). Correlation analyses were performed with the Statistical Package 
for Social Science (SPSS®) software version 19. 
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Results 
Clinical and neurologic evaluation  
 The mean duration of the disease was 9.4±4.4 years, UHDMRS score was 55.5±23.4, 
CAG repeats were 44.3±4.1. Average BMI was 21.9±4.0 kg/m2, neck circumference was 
36.0±3.7 cm. In the control group, mean age was 56.5±11.8 years (range: 38-76), average BMI 
was 26.3±8.5 kg/m2, neck circumference was 36.4±3.6 cm.  
 
  
HD patients Controls 
    Mean SD Total Mean SD Total 
Clinic and 
demographic 
data 
Age 57,30 12,24   56,50 11,85   
Gender 
  
14M, 16F 
  
14M, 16F 
Neck 35,99 3,75   36,37 3,60 
 BMI 21,96 4,01   26,27 8,54 
 Disease duration 9,43 4,49   
   UHDRS 55,55 23,43   
   CAG repeats 44,33 4,08   
    
 
Objective sleep evaluation 
PSG – Sleep structure 
 Useful sleep recordings were obtained in all patients and controls. One patient showed 
an almost total insomnia (TST = 15 minutes). HD patients, as compared to controls (C), showed 
shorter TST (HD: 303±105 min, C: 406±51 min, p<0.001), reduced Sleep Efficiency Index (SEI; 
HD: 63±21%, C: 93±5%, p<0.001), increased number of awakenings (HD: 16±10, C: 5±3, 
p<0.001), and consequently augmented Wake After Sleep Onset (WASO; HD: 132±88 min, C: 
40±29 min, p<0.001). Stages composition in HD was characterized by increased amount of N1 
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(HD: 15±9%, C: 9±7%, p=0.005), reduction of N3 (HD: 9±7%, C: 24±11%, p<0.001) and REM (HD: 
10±7%, C: 19±5%, p<0.001). HD patients showed higher arousal indexes (number of 
events/hour) in total sleep (HD: 37±23, C: 14±5, p<0.001), in NREM (HD: 37±24, C: 14±5, 
p<0.001), and REM (HD: 31±29, C: 13±5, p=0.006).  
 
PSG – Respiratory findings 
 Four patients presented PSG evidence of SDB: two had obstructive events (mild in one 
case, OAHI=5.9; and moderately severe in another, OHI=29.6 events/hour) and one had central 
events (CAHI=7.1 events/hour). One patient presented hemoglobin desaturations during sleep 
(ODI=16.7 events/hour) in absence of sleep-related respiratory events, possibly suggesting 
sleep-related hypoventilation. The patient with CSA and the patients with mild OSA had ESS 
scores above the cut-off. None of the subjects in the control group presented PSG findings 
consistent with SDB.  
  
PSG – Motor activity, PLMS, RBD  
 HD patients presented an overall increase of motor activity during wake and sleep. 
PLM were observed in all patients, both during pre-sleep wake and sleep. All patients, 
compared to controls, presented increased indexes of PLM at the lower limbs, during wake 
(PLMW; HD: 46±135, C: 0.5±1, p<0.001), total sleep (PLMS; HD: 18±19, C: 0.5±1, p<0.001), 
NREM (PLMS; HD: 18±19, C: 0.2±0.3, p<0.001) and REM (PLMS; HD: 15±24, C: 0.9±2, p=0.01). 
HD patients presented high indexes of PLM during wake and all sleep stages also in the upper 
limbs; recording of upper limbs PLM was not performed in the control group. Both upper and 
lower limbs PLM persisted during all sleep stages, but were consistently reduced during REM. 
No episode of RBD was observed in the V-PSG recordings; the two patients who had RBD-Q>5 
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did not show PSG evidence of RWA. None of the subjects in the control group presented PSG 
findings consistent with PLMS or RBD.  
 
   
Huntington Controls 
Mann-
Whitney 
      Mean DS Mean DS 
U-
test 
p 
Sleep structure 
  TIB 478,6 53,8 480,6 41,8 477,5 0,684 
  TST 303,5 105,8 406,3 51,5 728,5 <0,001 
  SPT 426,8 55,4 446,5 43,2 541,0 0,178 
  SEI 63,5 20,8 92,9 5,1 872,5 <0,001 
  SL 45,0 51,1 25,9 23,0 382,0 0,315 
  Aw 16,3 10,0 4,7 3,2 71,0 <0,001 
  WASO 132,2 88,1 40,2 29,5 110,0 <0,001 
  REM 9,8 7,2 19,2 5,1 777,0 <0,001 
  N1 14,6 8,9 9,0 7,3 261,0 0,005 
  N2 36,7 17,9 38,9 11,6 445,0 0,941 
  N3 9,0 7,4 23,8 10,7 801,0 <0,001 
  Wake 29,6 21,0 24,8 44,1 232,0 0,001 
  Arousal total 36,7 23,4 13,9 4,9 146,5 <0,001 
  
Arousal 
NREM 
37,5 24,3 13,9 5,1 154,0 <0,001 
  Arousal REM 31,1 29,4 13,5 4,7 263,5 0,006 
                  
Respiratory results 
Central 
Apneas 0,5 1,9 0,7 1,3 621,0 0,004 
Hypopneas 0,3 0,7 0,1 0,3 414,0 0,494 
Mixed 
Apneas 0,0 0,0 0,1 0,3 540,5 0,024 
Hypopneas 0,0 0,0 0,0 0,0 465,0 0,317 
Obstructive 
Apneas 0,5 1,3 1,0 1,6 605,0 0,012 
Hypopneas 1,1 4,7 1,3 1,7 622,5 0,006 
    
 
  
 
  
  
ODI 
Total sleep 3,3 3,9 3,3 2,0 531,0 0,231 
NREM 3,0 3,6 2,7 1,8 535,5 0,206 
REM 5,8 9,6 5,3 3,3 574,5 0,063 
                  
PLM         
Wake 
Lower limbs 
46,0 135,0 0,5 1,0 46,5 <0,001 
Sleep 17,6 19,5 0,5 1,4 0,0 <0,001 
NREM 17,9 19,2 0,2 0,3 2,0 <0,001 
REM 15,1 23,8 0,9 2,2 284,0 0,010 
    
 
  
 
  
  
Wake 
Upper limbs 
68,1 188,6 na na 
  
Sleep 20,9 27,6 na na 
  
NREM 21,5 27,6 na na 
  
REM 15,7 26,7 na na   
 
 Detailed results of PLM scoring, in patients and controls, in lower and upper limbs, and 
values of the periodicity index in HD patients during wake and sleep,  are shown in the table 
below.  
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  Lower limbs   Upper limbs 
  
Patients Controls Patients Controls 
 
Patients 
PLMW PI PLMW PLMS PI PLMS   PLMW PI PLMS PI 
1 12,0 0,582 0,1 15,6 0,824 0,1 
 
72,2 0,672 34,4 0,714 
2 58,8 0,737 0,2 19,0 0,732 0,0 
 
82,0 0,882 3,9 0,699 
3 13,2 0,755 0,3 1,3 0,986 0,0 
 
45,2 0,769 5,6 0,852 
4 13,5 0,792 1,2 16,6 0,841 1,0 
 
13,0 0,659 85,3 0,869 
5 89,6 0,820 0,6 3,2 0,679 1,1 
 
170,5 0,771 52,5 0,904 
6 8,1 0,907 0,3 3,8 0,852 0,2 
 
54,1 0,848 35,6 0,836 
7 90,5 0,647 0,0 21,7 0,846 0,0 
 
71,9 0,849 11,5 0,871 
8 11,1 0,794 0,0 22,3 0,736 0,0 
 
44,8 0,659 1,6 0,869 
9 8,8 0,742 0,0 4,0 0,759 0,1 
 
82,3 0,793 37,2 0,941 
10 147,8 0,702 0,1 112,4 0,789 0,2 
 
28,9 0,777 8,3 0,867 
11 59,9 0,658 0,2 6,3 0,765 0,0 
 
72,3 0,817 5,0 0,751 
12 13,0 0,872 0,3 17,0 0,739 0,0 
 
52,4 0,802 64,0 0,749 
13 52,4 0,716 0,4 6,0 0,744 0,0 
 
49,0 0,894 5,3 0,768 
14 50,9 0,735 1,0 19,8 0,825 0,0 
 
43,5 0,911 14,1 0,730 
15 55,3 0,614 0,0 16,2 0,691 1,3 
 
80,5 0,912 1,4 0,758 
16 49,4 0,714 0,0 2,1 0,894 1,2 
 
57,3 0,900 3,3 0,698 
17 36,9 0,751 0,3 16,6 0,735 0,0 
 
91,0 0,514 1,0 0,891 
18 8,1 0,717 0,3 16,6 0,769 0,0 
 
53,5 0,899 22,0 0,864 
19 71,0 0,810 0,2 17,1 0,781 0,3 
 
106,5 0,872 4,6 0,854 
20 50,9 0,832 0,0 16,1 0,746 4,2 
 
82,9 0,733 14,0 0,803 
21 75,0 0,863 0,0 17,7 0,779 0,0 
 
134,0 0,758 18,6 0,694 
22 54,0 0,865 2,3 24,4 0,719 3,2 
 
49,5 0,652 29,4 0,657 
23 67,6 0,766 1,0 2,4 0,698 0,0 
 
52,7 0,843 3,5 0,912 
24 13,1 0,816 1,2 5,5 0,841 0,0 
 
60,6 0,901 5,5 0,851 
25 124,0 0,751 0,0 23,3 0,867 0,0 
 
113,5 0,752 64,3 0,764 
26 42,5 0,824 0,0 19,0 0,906 0,0 
 
42,3 0,847 27,5 0,781 
27 37,6 0,735 2,1 21,2 0,867 0,2 
 
41,8 0,865 28,6 0,753 
28 42,4 0,614 0,6 18,3 0,899 0,1 
 
80,5 0,789 30,2 0,779 
29 10,6 0,698 0,0 22,9 0,847 0,5 
 
54,6 0,764 2,1 0,801 
30 11,2 0,751 1,2 20,6 0,901 0,3   58,7 0,698 6,6 0,659 
Mean 46,0 0,753 0,5 17,6 0,802 0,5 
 
68,1 0,793 20,9 0,798 
SD 35,4 0,080 0,6 19,4 0,076 1,0 
 
31,9 0,097 22,0 0,079 
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Subjective sleep evaluation 
 Twenty-nine subject were evaluate for sleepiness (one subject did not perform the 
Bologna Q). ESS score was above the cut-off in 6 subjects, Bologna Q detected ‘high risk’ of EDS 
in 7 cases. Thirty subjects were evaluated for sleep quality. PSQI score was above the cut-off in 
18 subjects. Using a HDQ score cut-off =3 (‘mild sleep disorder’), 10 subjects were poor 
sleepers. Two patients fulfilled the diagnostic criteria for RLS, and two had scores above the 
cut-off in the RBD-Q. The Berlin questionnaire identified 8 patients with high risk of OSAS 
(26.6%). The RBDQ identified 2 patients with scores above the cut-off value = 5, suggesting 
high risk of RBD. 
 
  HDQ PSQI Bologna Q Epworth Berlin scale 
IRLSSG 
criteria 
IRLSSG 
score 
RBD 
Q 
1 9 14 low 14 high 0 
 
9 
2 2 3 low 2 low 0 
 
1 
3 1 6 low 0 low 0 
 
1 
4 13 18 high 9 low 0 
 
4 
5 3 4 low 0 low 0 
 
1 
6 5 13 high 21 high 0 
 
3 
7 8 11 low 5 low 4 11 5 
8 2 4 low 6 low 0 
 
2 
9 4 10 low 2 low 0 
 
1 
10 2 7 high 3 low 0 
 
1 
11 2 3 low 3 low 0 
 
1 
12 2 6 high 4 high 0 
 
1 
13 3 9 low 1 low 0 
 
5 
14 5 5 low 6 low 0 
 
1 
15 
 
16 
 
11 low 0 
 
2 
16 2 4 low 6 high 0 
 
1 
17 1 5 low 10 high 0 
 
1 
18 1 5 low 4 low 0 
 
2 
19 4 7 high 14 low 0 
 
3 
20 2 4 low 7 low 0 
 
1 
21 1 5 low 7 low 0 
 
1 
22 3 6 low 3 high 0 
 
1 
23 1 2 low 3 low 0 
 
1 
24 12 17 high 14 low 0 
 
6 
25 4 4 low 6 low 4 9 5 
26 3 3 high 14 high 0 
 
1 
27 4 9 low 6 high 0 
 
2 
28 1 4 low 3 low 0 
 
1 
29 1 1 low 3 low 0 
 
2 
30 2 3 low 3 low 0   2 
Mean 3,55 6,93 
 
6,33 
 
0,27 
 
2,27 
SD 3,17 4,62 
 
5,02 
 
1,01 
 
1,96 
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As concern the concordance between scales, the EDS results were concordant in 24, and 
discordant in 5. The Cohen-K was 0.505, which suggests a ‘discrete’ concordance between the 
two scales. When we compared concordant (C) vs non-concordant subjects (NC), we observed 
that the NC subgroup had higher scores for depression (BDI score, C=4.8±4.6; NC=14.2±6.9; 
p=0.0008) and anxiety (Zung score, C=29.2±5.3; NC=36.4±9.2; p=0.024); no differences were 
computed for all the other clinical and subjective parameters.  
 In the evaluation of sleep quality, the results were concordant with the PSQI in 20 
subjects. The Cohen-K was 0.375, which suggests a ‘poor’ concordance between the two 
scales. Using a HDQ score cut-off =7 (‘significant sleep disorder’), 4 subjects were poor 
sleepers. The results were concordant with the PSQI in 16 subjects. The Cohen-K was 0.186, 
which again suggests a ‘poor’ concordance between the two scales.  
 
  Concordant  Discordant 
Cohen 
k 
Accuracy Sensibility  Specificity 
Bologna Q vs ESS 24 5 0,505 
   
PSQI vs HDQ (cut-off=3) 20 10 0,375 
   
PSQI vs HDQ (cut-off=7) 16 14 0,186 
   
PSQI vs SEI 18 12 0,062 0,600 0,167 0,889 
HDQ (cut-off=3) vs SEI 14 16 0,143 0,467 0,200 1,000 
       
PSQI components             
C2 vs SL 13 17 0,045 0,433 0,750 0,318 
C3 vs TST 15 15 -0,027 0,500 0,524 0,444 
C4 vs SEI 18 12 0,062 0,600 0,167 0,889 
C5 vs Aw 25 5 -0,056 0,833 0,000 0,862 
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Subjective vs objective measures 
 We measured the agreement of the subjective scales with objective data obtained 
from PSG recording. In particular, we compared the subjective sleep quality with the SEI; in 
this analysis, we used the HDQ cut-off =3, since it had showed a better concordance with the 
PSQI. At  PSG evaluation, poor sleep  was detected in 26 subject. Eighteen subjects were 
concordant with the PSQI evaluation, and 14 subjects were concordant with the HDQ. The 
Cohen-K between PSG and HDQ was 0.143, and between PSG and PSQI it was 0.062, 
suggesting ‘poor’ concordance between both scales and PSG. Furthermore, we matched the 
results of PSQI subcomponents with PSG scores. All comparisons showed poor or totally 
absent concordance between PSQI components and PSG findings; C4 and C5 showed a 
relatively high specificity (C4=0.889; C5=0.862) but low sensibility (C4=0.167; C5=0.000) with 
respect to PSG results, and C2 had the highest values of sensibility (0.750). Overall, C5 had the 
highest accuracy (0.833). The Berlin questionnaire identified 8 patients with high risk of OSAS 
(26.6%), whereas PSG showed that only 2 (6.6%) had PSG findings consistent with OSA; these 
data do not differ from the prevalence data observed in the general population50, 74. The RBDQ 
identified 2 patients with scores above the cut-off value = 5, suggesting high risk of RBD, not 
confirmed by V-PSG.  
 
EEG study42 
Wake 
 Statistical analysis demonstrated significant differences (threshold T = ±4.606; p<0.01) 
in the wake EEG between patients and controls in the delta frequency band. In particular, a 
significant increase of delta power was observed, in HD patients, in the voxels corresponding 
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to the Broadman areas (BAs) 3, 4 and 6 bilaterally, with stronger significance on the right 
hemisphere. No significant differences, in wake, were detected in the other frequency bands.  
 
 
 
NREM 
 In NREM sleep, HD patients showed a significant increase of the alpha power 
(threshold T = ±4.516; p<0.01) in the voxels corresponding to the BAs 4 and 6 bilaterally, again 
with stronger significance on the right hemisphere. HD patients also showed decreased theta 
power (threshold T = ±4.516; p<0.01) in the voxels corresponding to the BAs 23, 29 and 30 
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bilaterally. In the beta band, patients showed decreased power in the BA 30 in the left 
hemisphere (threshold T = ±4.516; p<0.01). No significant differences were detected in the 
delta and gamma frequency bands in NREM sleep. 
 
 
 
REM 
 During REM, HD patients presented a significant decrease of the theta and alpha 
power (threshold T = ±4.640; p<0.01) in the voxels corresponding to the BAs 23, 29, 30 and 31 
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bilaterally. No significant differences were detected in the other frequency bands in REM 
sleep.  
 
 
 
Clinical correlations 
 The analysis of correlations between clinical and sleep parameters showed that 
disease duration was significantly correlated with ESS score (Spearman ρ=0.420; p<0.02) but 
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not with PSG scores. UHDMRS correlated positively with the ESS score (Spearman ρ=0.475; 
p<0.005), and negatively with REM percentage (Spearman ρ=-0.524; p<0.002). No correlation 
between number of CAG repeats and sleep results was observed. The main clinical parameters 
(age, disease duration, clinical severity and CAG repeats) did not show any significant 
correlation with sleep scales. Conversely, all subjective sleep scores showed significant positive 
correlations with BDI, Zung-A and MOCI scores. In the EEG study, spectral power in Broadman 
Area  4 was significantly associated with: i) age and disease duration (in Wake), ii) BMI and 
disease duration (in REM); iii) UHDMRS (in NREM). No correlation were observed between EEG 
power spectra and CAG repeats.  
 
Wake 
 
REM 
 
NREM 
 
δ θ α β 
 
δ θ α β 
 
δ θ α β 
  L R L R L R L R   L R L R L R L R   L R L R L R L R 
Age 
  
+ + + 
                     
BMI - - 
       
- - - - 
             
Disease 
duration 
+ + + + 
  
+ 
      
+ + 
        
+ 
  
Disease 
burden                           
UHDMRS 
 
+ 
                  
+ + + + + + 
CAG 
repeats 
                                                    
 
 
Effect of drug treatment 
 Finally, in order to rule out the effect of pharmacological treatment, the HD group was 
split into 2 subgroups: patients taking neuroleptics or benzodiazepines, which can potentially 
affect sleep measures (n=18), and patient not assuming these drugs (n=12). The comparison 
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did not show any significant difference between the subgroups, in any of the clinical and PSG 
variables. Also the comparison of PLM indexes between patients taking the different class of 
drugs did not show any significant difference. 
  
33 
 
Discussion 
 The present paper describes the largest cohort of HD patients enrolled so far for a 
polysomnographic sleep study.  
 The results suggest that sleep is severely disrupted in HD patients. In particular, our HD 
patients had difficulties in initiating sleep (longer sleep latency than controls), and sleep was 
fragmented by frequent arousal and repeated, long lasting awakenings. As a result, sleep 
structure was characterized by increase of light sleep and decrease of deep sleep and REM. 
These findings, in particular REM sleep reduction, appear to be directly related with the clinical 
severity, measured by the UHDMRS. Concomitant sleep disorders were relatively uncommon 
in our sample. Two patients (6.6%) had symptoms of RLS, of mild-moderate severity; and two 
(6.6%) had PSG findings consistent with OSA. Daytime somnolence, measured by the ESS, was 
present in 8 patients (26.6%). Somnolence was present in 2/4 (50%) of the patients with PSG 
findings of SDB. These data do not differ from the prevalence data observed in the general 
population50, 74. This is in accordance with the result of a previous PSG study by Cuturic et al. 
(2009)30. In our sample, the prevalence of RBD was, once again, not different from that of the 
general population75. No episode of RBD was observed in the V-PSG recordings, and only two 
patients had, at the RBD-Q a score >5, which is considered the cut-off for the clinical suspicion 
of RBD. In V-PSG, these patients did not show RBD episodes or RWA. In our HD patients, 
nevertheless, motor activity during wake and sleep was considerably increased. All patients 
presented a variety of PLM during wake and sleep, involving both the upper and the lower 
limbs. PLMS persisted along all NREM sleep stages, and were markedly reduced during REM. 
Most PLM were associated with EEG arousals, suggesting that this motor activity may affect 
the structure of sleep. These data suggest that PLM may be a major pathogenic mechanism of 
sleep disruption and daytime sleepiness.  
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 The present data are in accordance with some previous reports available in literature, 
which suggest that sleep is severely affected in HD28, 29, 31, 32, 34, 36, 37. Conversely, some data do 
not confirm previous findings. In particular, a previous study by Arnulf et al. (2008)31 reported 
a higher prevalence of RBD in HD (up to 12%). In our sample, symptoms of RBD were reported 
in only two cases, and no episode of RBD was recorded in the V-PSG. As concerns the RBD-Q, it 
is known that  this questionnaire, which has a high sensitivity for RBD, poorly discriminated 
patients with the most challenging differential diagnoses such as sleepwalking or epilepsy. 
Analogously, it may be conceived that the continuous motor activity of HD patients during 
sleep might mimic some RBD phenomena. Other relevant differences between our population 
and that described by Arnulf et al. concern  the disease severity and the pharmacological 
treatment. Our patient were older, had longer disease duration and more severe motor 
impairment (mean UHDMRS score = 55.5 vs 25.4 in the Arnulf et al. study31). As a consequence 
of the clinical severity of our patients, we decided to perform the sleep study without any drug 
withdrawal. Even though this could bias some sleep measures, when we compared patients 
assuming neuroleptics or benzodiazepines with those assuming only amantadine or 
tetrabenazine, no difference was observed in clinical and sleep parameters. We observed in 
our HD patients a very high prevalence of PLM, both during pre-sleep wake and sleep, also 
involving upper limbs. Also in this respect, the greater clinical severity of our patients may 
account for the higher indexes of PLM as compared to that reported by Arnulf et al. Moreover, 
we decided to explore, in PSG, also the movements of the upper limbs, which were not 
recorded in previous studies. This technical issue may further explain the differences in PLM 
indexes. Recently, the role of caudate nucleus in sleep pathology has been evaluated76. 
Moreover, experimental animal models suggest that caudate lesions may induce behavioural 
restlessness and hyper-responsivity, consequent to failing of inhibitory modulation of sensory 
input77. Electrical stimulation of the caudate enhances cortical synchronization, inhibits 
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behavioural and autonomic nervous system responses to stimuli78, and suppresses neuronal 
firing in the reticular formation, thalamus, hypothalamus and cortex79. Also in humans the  
stimulation of the caudate reduces cortical excitability80. Taken together, these data may 
suggest that the caudate degenerative process observed in HD account for the increased 
arousability, increased motor activity during wake and sleep (originating PLM), reduction of 
SWS and in particular of REM sleep and, overall, a general sleep disruption.34, 35   
 
 As concerns the subjective sleep evaluation, our data suggest, overall, that the 
subjective evaluation of sleep in HD patients shows a poor correlation  with PSG results. As 
concern sleep quality, both the PSQI and the more specific HDQ showed relatively good 
specificity in detecting sleep disruption (in particular when this was evaluated by the SEI), but 
very low sensibility and, consequently, accuracy. Moreover, the two questionnaire presented a 
low degree of agreement (14/30 discordant subjects, Cohen k=0.186 with a 7-points HDQ cut-
off, reduced to 10/30 discordant subjects, Cohen k=0.375 with a 3-points HDQ cut-off). Within 
the PSQI subcomponents, the C4 was the most specific (compared to SEI) while C5 was the 
most accurate (compared to awakenings). This suggests that the clinical application of these 
scales can lead to an underestimation of sleep disorders in HD patients. As concern the 
evaluation of EDS, the results of our scales could not be compared to the gold-standard 
procedure for EDS, that is MSLT, not performed in our study. Nevertheless, the scores of ESS 
and Bologna Q showed poor concordance, suggesting that different subjective methods used 
for evaluation of sleepiness can lead to different results (5/29 discordant subjects, Cohen 
k=0.505). Also the scales for OSA (Berlin Q) and RBD (RBD-Q) showed poor agreement with V-
PSG data. This suggests that both these tools overestimate the prevalence of sleep disorders. 
Several elements could account for the discrepancies between subjective and objective data. 
In theory, these discrepancies could depend on age, gender, disease duration or severity 
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(expressed as UHMDRS), number of CAG repeats. When we compared these clinical data 
between the subgroups of  ‘concordant’ (concordance of objective and subjective findings) and 
‘discordants’ patients, we found no significant difference. Conversely, we observed that the 
‘discordant’ subgroup showed high scores at the depression, anxiety and obsessive-compulsive 
scale. Moreover, we observed no correlation between clinical variables and subjective sleep 
scores, and, as opposite, significant direct correlations between the sleep and psychometric 
scales. This seems to suggest that the subjective perception of poor sleep, somnolence and 
presence of sleep disorders is deeply influenced by mood disorder, anxiety and obsessive-
compulsive symptoms. Sleep quality and duration are often mispercepted in patients with 
sleep disorders. Such misperception usually consist in an underestimation of sleep, and only a 
small minority of poor sleepers overestimate their sleep. Our results suggest that at least a 
part of the HD population falls in this latter category. One possible explanation for this 
phenomenon is the anosognosia which HD patients develop in the course of their disease: 
people with HD may show reduced awareness of physical and mental changes in themselves81. 
 
 The EEG study confirms that HD patients present significant EEG modification as 
compared to controls42. These modifications change across the wake and sleep stages. During 
wake, we observed an increase of delta activity, specifically localized on the sensory, motor 
and premotor areas (BAs 3, 4 and 6), bilaterally, with a right-side predominance. Conversely, 
during NREM sleep, the motor and premotor cortices (BAs 4 and 6) showed an increase of 
alpha activity. Finally, during REM sleep, no modifications of activity were observed in motor 
regions, while a diffuse decrease of alpha and theta power was seen in limbic structure, and 
particularly in the posterior cingulated cortex (BAs 23, 29, 30 and 31 bilaterally). These findings 
suggest that EEG modifications may be related to the motor dysfunction of HD.25 The increased 
delta activity, during wake, might reflect a motor cortex dysfunction or, alternatively, an 
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increased inhibitory activity aimed to counterbalance the pathologic motor phenomena. 
Analogously, during NREM sleep, we observed an increase of alpha activity, which could 
represent the electrophysiological correlate of the sustained motor activity detected in PSG 
recording during NREM sleep30, 31, 82.  
 
 
 
 The study design did not allow to evaluate drug-free HD patients;  for this reason, 
some results could be biased by pharmacological effects. Most of our patients, for the 
treatment of involuntary movements, were assuming neuroleptics and tetrabenazine. 
Tetrabenazine is a drug whose effect on the scalp EEG have not been systematically 
investigated. Conversely, the effects of neuroleptics on the EEG are well known: both 
'conventional' and 'atypical' antipsychotics may increase the high-frequency rhythms, namely 
alpha and beta power83. One half of the patient were on antiepileptic drugs (AEDs, in most 
cases sodium valproate - VPA), used not for seizures but as mood stabilizers. Chronic AEDs 
administration can increase EEG theta power, and can modify (either increase or decrease) 
alpha mean frequency84. Only few patients, at the moment of the study, were assuming 
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benzodiazepines (BZD). BZD can increase fast-frequency EEG components in wake and sleep, 
and can decrease theta and delta power during sleep85. Pharmacological effects on EEG are 
diffuse on the entire scalp, whereas most of the spectral modifications observed in our study 
were local; this suggests that the EEG modifications described are more likely due to the 
disease rather than to the treatments. Though HD is a degenerative disease which affects 
prominently sub-cortical structures and, in particular, the caudate nucleus, several 
morphological and neurophysiological data indicate that the brain cortex is diffusely involved86-
88. In particular, cortical degeneration has been demonstrated in motor, pre-motor89-91 and 
visual88 areas. Functional compensation has been reported in early Alzheimer disease to offset 
neuronal loss; it is likely that such mechanism  may also occur in other neurodegenerative 
diseases, particularly in HD92. Malejko et al. (2014) described, in HD patients, enhanced fMRI 
signalling  in the striatum as well as in the orbitofrontal cortex/anterior insula, and interpreted 
these findings as the evidence for "functional compensation in pre-manifest HD,  which may 
suggest a defence mechanism in neuro-degeneration"92. The PREDICT-HD study indicated that 
the prodromal phase of HD is associated with abnormal interhemispheric interactions among 
motor areas, and that these changes may contribute to increased motor symptoms and 
deficits in the executive control of movement89.  Another study provided evidence of early 
compensatory activation (hyperactivation) of right-hemisphere inhibition and attention 
reorienting centers, despite an absence of cortical atrophy93.  In our study, the EEG 
modifications observed in the motor areas were bilateral, though more evident on the right 
side (Figures 1, 2). Our results confirm that the response inhibition in HD is associated with 
altered functioning in brain networks that govern inhibition and motor control.94 This 
hypothesis is further supported by the absence of EEG modifications in motor areas during 
REM, when the motor activity is markedly reduced82 (Figure 4). EEG power spectra measured 
in the motor areas, during wake and sleep, showed significant correlations with several clinical 
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indexes (age, disease duration, burden, UHDMRS, BMI) which all reflect, directly or indirectly, 
the severity of the disease. When comparing our results with previous literature, however, it 
must be considered that in our study we did not enrol prodromal HD subjects.  Moreover, HD 
patients showed modification of EEG activity in limbic areas (particularly in the posterior 
cingulate cortex) during sleep: these consisted in reduced theta and alpha power in REM, and 
reduced theta power in NREM. The slow oscillations occurring during NREM sleep and theta 
oscillations present during REM sleep have been considered of critical relevance for memory 
formation and consolidation.95, 96 Therefore, these modification could be related to the 
memory impairment described in HD: it has been reported that the cingulate cortex  
undergoes structural degeneration during early stages of HD; and that cingulate dysfunction 
may contribute to deficits in mood, emotional processing, and visual working memory in HD.97 
 Several Authors have studied EEG features in HD and in presymptomatic subjects98-117.  
 
 
 
 Most Authors have described decrease of the alpha power99, 100, 104, 106-111, 113-117 and 
increase of slow frequencies (delta and theta) 100, 107-109, 111, 114-116. In a LORETA EEG study, 
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performed during controlled wake, Painfold et al. (2011)116 observed  that  theta, alpha and 
beta power were diffusely decreased from early to late stages of the disease; whereas in the 
advanced disease stages patients showed a significant increase in delta power, mainly in the 
right orbitofrontal cortex116. Most studies have focused on correlations between EEG and 
clinical parameters. In previous studies, EEG modifications have been related to clinical 
state101, 106, 109, 111, 114-116, cognitive impairment107, 108, 115, 116, cortical atrophy103, 105, CAG 
repeats109, 111, 114, 117, evolution with age100. Other Authors have looked for a predictive value of 
EEG in subjects ‘at risk’ of developing HD98, 102. Most studies, anyway, focused on wake EEG, 
and only three reports, with small samples of HD patients, investigated EEG during 
spontaneous101, 105 or induced104 sleep with discordant results concerning the modifications of 
sleep spindles. When compared to previous literature, our study confirmed the increase in 
low-frequency bands power in HD patients during wake, but did not show confirm reduction in 
the alpha power. Comparable quantitative data on the sleep EEG in HD, to the best of our 
knowledge, are not available. The interpretation of the mechanism of sleep-related motor 
pattern is a clinically relevant issue in HD, since sleep disorders can worsen cognitive 
performance and quality of life. In this context, we believe that the definition of abnormalities 
in cortical activity, evaluated by means of scalp EEG, can help to understand the pathogenic 
mechanism of the motor disorder and can orient therapeutic strategies. 
 In conclusion, our EEG data suggest a defined pattern of motor cortex dysfunction 
during wake and sleep, which correlates with the clinical and polysomnographic evidence of 
increased motor activity during wake and NREM, and nearly absent motor abnormalities in 
REM. It could be hypothesized that EEG modifications reflect motor cortex impairment or, 
conversely, an effort to counterbalance abnormal motor output. Further studies, including 
modulation of cortical excitability, could help to understand the cortical neurophysiology of 
HD. As stated in the Methods, in moderate-to-severe HD patients, the presence of severe 
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motor, behavioural and psychiatric symptoms does not allow to withdraw pharmacological 
therapies; future studies are needed, which should enrol  prodromal or mild HD subjects. We 
believe that characterization of these mechanisms of cortical motor control could support 
therapeutic strategies. 
 
Conclusions 
 Though our results appear strikingly different from those reported in the previous 
papers of the French group118-120, we believe that we may likely be describing the same 
phenomenon with different words. We agree that the complex of motor behavior observed 
during sleep in HD patients is not fully described by the term 'periodic limb movement', since it 
involves the trunk and often the whole body. Nevertheless our observations suggest that these 
abnormal motor activity, seen over long periods of time, show an evident periodicity. All the 
movements recorded in video-PSG are characterized by an EMG activation of the upper and 
lower limbs, sometimes followed by a sequence of more complex motor activation. Also, we 
fully agree that cortical arousals are strictly associated with such motor disorder. We suggest 
that periodic movements and concomitant arousal fluctuations may be explained as a an 
atypical periodic movement is sleep, occurring in patients with an extreme disregulation of 
motor control. The interpretation of the mechanism of sleep-related motor pattern in HD is 
relevant since it can orient therapeutic strategies121.  
  
42 
 
References 
1. A novel gene containing a trinucleotide repeat that is expanded and unstable on 
Huntington's disease chromosomes. The Huntington's Disease Collaborative Research 
Group. Cell 1993;72:971-983. 
2. Cattaneo E, Zuccato C, Tartari M. Normal huntingtin function: an alternative approach 
to Huntington's disease. Nature reviews Neuroscience 2005;6:919-930. 
3. Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical 
treatment. The Lancet Neurology 2011;10:83-98. 
4. Walker FO. Huntington's disease. Lancet 2007;369:218-228. 
5. Yoon SR, Dubeau L, de Young M, Wexler NS, Arnheim N. Huntington disease expansion 
mutations in humans can occur before meiosis is completed. Proceedings of the 
National Academy of Sciences of the United States of America 2003;100:8834-8838. 
6. Shao J, Diamond MI. Polyglutamine diseases: emerging concepts in pathogenesis and 
therapy. Human molecular genetics 2007;16 Spec No. 2:R115-123. 
7. Tobin AJ, Signer ER. Huntington's disease: the challenge for cell biologists. Trends in 
cell biology 2000;10:531-536. 
8. Fang Q, Strand A, Law W, et al. Brain-specific proteins decline in the cerebrospinal fluid 
of humans with Huntington disease. Molecular & cellular proteomics : MCP 
2009;8:451-466. 
9. Gonzales E, Yin J. Drosophila Models of Huntington's Disease exhibit sleep 
abnormalities. PLoS currents 2010;2. 
10. Landles C, Bates GP. Huntingtin and the molecular pathogenesis of Huntington's 
disease. Fourth in molecular medicine review series. EMBO reports 2004;5:958-963. 
11. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR, International 
Huntington's Disease Collaborative G. A new model for prediction of the age of onset 
and penetrance for Huntington's disease based on CAG length. Clinical genetics 
2004;65:267-277. 
12. Harper PS. Huntington disease and the abuse of genetics. American journal of human 
genetics 1992;50:460-464. 
13. Foroud T, Gray J, Ivashina J, Conneally PM. Differences in duration of Huntington's 
disease based on age at onset. Journal of neurology, neurosurgery, and psychiatry 
1999;66:52-56. 
43 
 
14. Halliday GM, McRitchie DA, Macdonald V, Double KL, Trent RJ, McCusker E. Regional 
specificity of brain atrophy in Huntington's disease. Experimental neurology 
1998;154:663-672. 
15. Vonsattel JP, Keller C, Del Pilar Amaya M. Neuropathology of Huntington's disease. 
Handbook of clinical neurology 2008;89:599-618. 
16. Rosas HD, Koroshetz WJ, Chen YI, et al. Evidence for more widespread cerebral 
pathology in early HD: an MRI-based morphometric analysis. Neurology 2003;60:1615-
1620. 
17. Rosas HD, Salat DH, Lee SY, et al. Cerebral cortex and the clinical expression of 
Huntington's disease: complexity and heterogeneity. Brain : a journal of neurology 
2008;131:1057-1068. 
18. Ross CA, Becher MW, Colomer V, Engelender S, Wood JD, Sharp AH. Huntington's 
disease and dentatorubral-pallidoluysian atrophy: proteins, pathogenesis and 
pathology. Brain pathology 1997;7:1003-1016. 
19. Siesling S, van Vugt JP, Zwinderman KA, Kieburtz K, Roos RA. Unified Huntington's 
disease rating scale: a follow up. Movement disorders : official journal of the 
Movement Disorder Society 1998;13:915-919. 
20. Cummings JL. Behavioral and psychiatric symptoms associated with Huntington's 
disease. Advances in neurology 1995;65:179-186. 
21. Diamond R, White RF, Myers RH, et al. Evidence of presymptomatic cognitive decline in 
Huntington's disease. Journal of clinical and experimental neuropsychology 
1992;14:961-975. 
22. Lemiere J, Decruyenaere M, Evers-Kiebooms G, Vandenbussche E, Dom R. Longitudinal 
study evaluating neuropsychological changes in so-called asymptomatic carriers of the 
Huntington's disease mutation after 1 year. Acta neurologica Scandinavica 
2002;106:131-141. 
23. Lemiere J, Decruyenaere M, Evers-Kiebooms G, Vandenbussche E, Dom R. Cognitive 
changes in patients with Huntington's disease (HD) and asymptomatic carriers of the 
HD mutation--a longitudinal follow-up study. Journal of neurology 2004;251:935-942. 
24. Reading SA, Dziorny AC, Peroutka LA, et al. Functional brain changes in 
presymptomatic Huntington's disease. Annals of neurology 2004;55:879-883. 
25. Folstein SE, Leigh RJ, Parhad IM, Folstein MF. The diagnosis of Huntington's disease. 
Neurology 1986;36:1279-1283. 
44 
 
26. Andrich J, Saft C, Ostholt N, Muller T. Assessment of simple movements and 
progression of Huntington's disease. Journal of neurology, neurosurgery, and 
psychiatry 2007;78:405-407. 
27. Andrich J, Saft C, Ostholt N, Muller T. Complex movement behaviour and progression 
of Huntington's disease. Neuroscience letters 2007;416:272-274. 
28. Taylor N, Bramble D. Sleep disturbance and Huntingdon's disease. Br J Psychiatry 
1997;171:393. 
29. Goodman AO, Rogers L, Pilsworth S, et al. Asymptomatic sleep abnormalities are a 
common early feature in patients with Huntington's disease. Curr Neurol Neurosci Rep 
2011;11:211-217. 
30. Cuturic M, Abramson RK, Vallini D, Frank EM, Shamsnia M. Sleep patterns in patients 
with Huntington's disease and their unaffected first-degree relatives: a brief report. 
Behavioral sleep medicine 2009;7:245-254. 
31. Arnulf I, Nielsen J, Lohmann E, et al. Rapid eye movement sleep disturbances in 
Huntington disease. Arch Neurol 2008;65:482-488. 
32. Emser W, Brenner M, Stober T, Schimrigk K. Changes in nocturnal sleep in Huntington's 
and Parkinson's disease. J Neurol 1988;235:177-179. 
33. Videnovic A, Leurgans S, Fan W, Jaglin J, Shannon KM. Daytime somnolence and 
nocturnal sleep disturbances in Huntington disease. Parkinsonism Relat Disord 
2009;15:471-474. 
34. Wiegand M, Moller AA, Lauer CJ, et al. Nocturnal sleep in Huntington's disease. J 
Neurol 1991;238:203-208. 
35. Wiegand M, Moller AA, Schreiber W, Lauer C, Krieg JC. Brain morphology and sleep 
EEG in patients with Huntington's disease. Eur Arch Psychiatry Clin Neurosci 
1991;240:148-152. 
36. Hurelbrink CB, Lewis SJ, Barker RA. The use of the Actiwatch-Neurologica system to 
objectively assess the involuntary movements and sleep-wake activity in patients with 
mild-moderate Huntington's disease. J Neurol 2005;252:642-647. 
37. Morton AJ, Wood NI, Hastings MH, Hurelbrink C, Barker RA, Maywood ES. 
Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. J 
Neurosci 2005;25:157-163. 
45 
 
38. Pallier PN, Maywood ES, Zheng Z, et al. Pharmacological imposition of sleep slows 
cognitive decline and reverses dysregulation of circadian gene expression in a 
transgenic mouse model of Huntington's disease. J Neurosci 2007;27:7869-7878. 
39. Pallier PN, Morton AJ. Management of sleep/wake cycles improves cognitive function 
in a transgenic mouse model of Huntington's disease. Brain Res 2009;1279:90-98. 
40. Franzen PL, Buysse DJ. Sleep disturbances and depression: risk relationships for 
subsequent depression and therapeutic implications. Dialogues Clin Neurosci 
2008;10:473-481. 
41. Hogarth P, Kayson E, Kieburtz K, et al. Interrater agreement in the assessment of motor 
manifestations of Huntington's disease. Mov Disord 2005;20:293-297. 
42. Piano C, Mazzucchi E, Bentivoglio AR, et al. Wake and sleep EEG in Huntington disease 
patients. An eLORETA study and review of the literature. Clinical EEG and neuroscience 
: official journal of the EEG and Clinical Neuroscience Society in press. 
43. Vaccarino AL, Anderson K, Borowsky B, et al. An item response analysis of the motor 
and behavioral subscales of the unified Huntington's disease rating scale in huntington 
disease gene expansion carriers. Mov Disord 2011;26:877-884. 
44. Orth M, Schwenke C. Age-at-onset in Huntington disease. PLoS currents 
2011;3:RRN1258. 
45. Curcio G, Tempesta D, Scarlata S, et al. Validity of the Italian Version of the Pittsburgh 
Sleep Quality Index (PSQI). Neurol Sci 2012. 
46. Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep 
Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 
1989;28:193-213. 
47. Vignatelli L, Plazzi G, Barbato A, et al. Italian version of the Epworth sleepiness scale: 
external validity. Neurological sciences : official journal of the Italian Neurological 
Society and of the Italian Society of Clinical Neurophysiology 2003;23:295-300. 
48. Rinaldi R, Vignatelli L, D'Alessandro R, et al. Validation of symptoms related to 
excessive daytime sleepiness. Neuroepidemiology 2001;20:248-256. 
49. Netzer NC, Stoohs RA, Netzer CM, Clark K, Strohl KP. Using the Berlin Questionnaire to 
identify patients at risk for the sleep apnea syndrome. Ann Intern Med 1999;131:485-
491. 
50. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J. Restless 
legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report 
46 
 
from the restless legs syndrome diagnosis and epidemiology workshop at the National 
Institutes of Health. Sleep Med 2003;4:101-119. 
51. Stiasny-Kolster K, Mayer G, Schafer S, Moller JC, Heinzel-Gutenbrunner M, Oertel WH. 
The REM sleep behavior disorder screening questionnaire--a new diagnostic 
instrument. Mov Disord 2007;22:2386-2393. 
52. Zung WW. A rating instrument for anxiety disorders. Psychosomatics 1971;12:371-379. 
53. Furlanetto LM, Mendlowicz MV, Romildo Bueno J. The validity of the Beck Depression 
Inventory-Short Form as a screening and diagnostic instrument for moderate and 
severe depression in medical inpatients. Journal of affective disorders 2005;86:87-91. 
54. Dominguez RA, Jacobson AF, de la Gandara J, Goldstein BJ, Steinbook RM. Drug 
response assessed by the Modified Maudsley Obsessive-Compulsive Inventory. 
Psychopharmacol Bull 1989;25:215-218. 
55. American Academy of Sleep Medicine, ed. The International Classification of Sleep 
Disorders - Diagnostic and Coding Manual. Third edition. Westchester, IL2014. 
56. Silber MH, Ancoli-Israel S, Bonnet MH, et al. The visual scoring of sleep in adults. 
Journal of clinical sleep medicine : JCSM : official publication of the American Academy 
of Sleep Medicine 2007;3:121-131. 
57. Iber C, Ancoli-Israel S, Chesson A, Quan SF. The AASM manual for scoring of sleep and 
associated events: rules, terminology and technical specifications. 2007;1st ed. 
Westchester, IL:American Academy of Sleep Medicine. 
58. Zucconi M, Ferri R, Allen R, et al. The official World Association of Sleep Medicine 
(WASM) standards for recording and scoring periodic leg movements in sleep (PLMS) 
and wakefulness (PLMW) developed in collaboration with a task force from the 
International Restless Legs Syndrome Study Group (IRLSSG). Sleep medicine 
2006;7:175-183. 
59. Ferri R, Zucconi M, Manconi M, Plazzi G, Bruni O, Ferini-Strambi L. New approaches to 
the study of periodic leg movements during sleep in restless legs syndrome. Sleep 
2006;29:759-769. 
60. Babiloni C, Carducci F, Lizio R, et al. Resting state cortical electroencephalographic 
rhythms are related to gray matter volume in subjects with mild cognitive impairment 
and Alzheimer's disease. Hum Brain Mapp 2013;34:1427-1446. 
47 
 
61. Pascual-Marqui RD, Esslen M, Kochi K, Lehmann D. Functional imaging with low-
resolution brain electromagnetic tomography (LORETA): a review. Methods Find Exp 
Clin Pharmacol 2002;24 Suppl C:91-95. 
62. Piano C, Losurdo A, Della Marca G, et al. Polysomnographic Findings and Clinical 
Correlates in Huntington Disease: A Cross-Sectional Cohort Study. Sleep 2015;38:1489-
1495. 
63. Pascual-Marqui RD, Michel CM, Lehmann D. Low resolution electromagnetic 
tomography: a new method for localizing electrical activity in the brain. Int J 
Psychophysiol 1994;18:49-65. 
64. Talairach J, Tournoux P. Co-Planar Stereotaxic Atlas of the Human Brain. . Stuttgart: 
Thieme 1988. 
65. Kreiter AK, Singer W. Oscillatory Neuronal Responses in the Visual Cortex of the Awake 
Macaque Monkey. Eur J Neurosci 1992;4:369-375. 
66. Murphy TH, Blatter LA, Wier WG, Baraban JM. Spontaneous synchronous synaptic 
calcium transients in cultured cortical neurons. J Neurosci 1992;12:4834-4845. 
67. Grave de Peralta-Menendez R, Gonzalez-Andino SL. A critical analysis of linear inverse 
solutions to the neuroelectromagnetic inverse problem. IEEE Trans Biomed Eng 
1998;45:440-448. 
68. Grave de Peralta Menendez R, Gonzalez Andino SL, Morand S, Michel CM, Landis T. 
Imaging the electrical activity of the brain: ELECTRA. Hum Brain Mapp 2000;9:1-12. 
69. Kanady JC, Drummond SP, Mednick SC. Actigraphic assessment of a polysomnographic-
recorded nap: a validation study. Journal of sleep research 2011;20:214-222. 
70. Tilmanne J, Urbain J, Kothare MV, Wouwer AV, Kothare SV. Algorithms for sleep-wake 
identification using actigraphy: a comparative study and new results. Journal of sleep 
research 2009;18:85-98. 
71. Nichols TE, Holmes AP. Nonparametric permutation tests for functional neuroimaging: 
a primer with examples. Hum Brain Mapp 2002;15:1-25. 
72. Friston KJ, Frith CD, Liddle PF, Dolan RJ, Lammertsma AA, Frackowiak RS. The 
relationship between global and local changes in PET scans. J Cereb Blood Flow Metab 
1990;10:458-466. 
73. Friston KJ, Frith CD, Liddle PF, Frackowiak RS. Comparing functional (PET) images: the 
assessment of significant change. J Cereb Blood Flow Metab 1991;11:690-699. 
48 
 
74. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-
disordered breathing among middle-aged adults. The New England journal of medicine 
1993;328:1230-1235. 
75. Kang SH, Yoon IY, Lee SD, Han JW, Kim TH, Kim KW. REM sleep behavior disorder in the 
Korean elderly population: prevalence and clinical characteristics. Sleep 2013;36:1147-
1152. 
76. Stoffers D, Altena E, van der Werf YD, et al. The caudate: a key node in the neuronal 
network imbalance of insomnia? Brain 2014;137:610-620. 
77. Villablanca JR, Marcus RJ, Olmstead CE. Effects of caudate nuclei or frontal cortex 
ablations in cats. II. Sleep-wakefulness, EEG, and motor activity. Exp Neurol 
1976;53:31-50. 
78. Wilcott RC. Skeletal and automatic inhibition from low-frequency electrical stimulation 
of the cat's brain. Neuropsychologia 1974;12:487-496. 
79. Siegel J, Morton CR, Sandkuhler J, Xiao HM, Zimmermann M. Spinal neuronal inhibition 
and EEG synchrony by electrical stimulation in subcortical forebrain regions of the cat. 
Exp Brain Res 1986;62:363-372. 
80. Chkhenkeli SA, Sramka M, Lortkipanidze GS, et al. Electrophysiological effects and 
clinical results of direct brain stimulation for intractable epilepsy. Clin Neurol 
Neurosurg 2004;106:318-329. 
81. Sitek EJ, Thompson JC, Craufurd D, Snowden JS. Unawareness of deficits in 
Huntington's disease. Journal of Huntington's disease 2014;3:125-135. 
82. Piano C, Losurdo A, Della Marca G, et al. Polysomnographic findings and clinical 
correlates in Huntington disease. A cross-sectional cohort study. . Sleep 2015;In press.: 
http://www.journalsleep.org/Accepted.aspx. 
83. Yoshimura M, Koenig T, Irisawa S, et al. A pharmaco-EEG study on antipsychotic drugs 
in healthy volunteers. Psychopharmacology 2007;191:995-1004. 
84. Clemens B, Menes A, Piros P, et al. Quantitative EEG effects of carbamazepine, 
oxcarbazepine, valproate, lamotrigine, and possible clinical relevance of the findings. 
Epilepsy research 2006;70:190-199. 
85. Bastien CH, LeBlanc M, Carrier J, Morin CM. Sleep EEG power spectra, insomnia, and 
chronic use of benzodiazepines. Sleep 2003;26:313-317. 
86. Novak MJ, Seunarine KK, Gibbard CR, et al. Basal ganglia-cortical structural 
connectivity in Huntington's disease. Human brain mapping 2015;36:1728-1740. 
49 
 
87. Rub U, Hentschel M, Stratmann K, et al. Huntington's disease (HD): degeneration of 
select nuclei, widespread occurrence of neuronal nuclear and axonal inclusions in the 
brainstem. Brain pathology 2014;24:247-260. 
88. Rub U, Seidel K, Vonsattel JP, et al. Huntington's Disease (HD): Neurodegeneration of 
Brodmann's Primary Visual Area 17 (BA17). Brain pathology 2014. 
89. Koenig KA, Lowe MJ, Harrington DL, et al. Functional connectivity of primary motor 
cortex is dependent on genetic burden in prodromal Huntington disease. Brain 
connectivity 2014;4:535-546. 
90. Matsui JT, Vaidya JG, Wassermann D, et al. Prefrontal cortex white matter tracts in 
prodromal Huntington disease. Human brain mapping 2015. 
91. Wolf RC, Sambataro F, Vasic N, et al. Abnormal resting-state connectivity of motor and 
cognitive networks in early manifest Huntington's disease. Psychological medicine 
2014;44:3341-3356. 
92. Malejko K, Weydt P, Sussmuth SD, Gron G, Landwehrmeyer BG, Abler B. Prodromal 
Huntington disease as a model for functional compensation of early 
neurodegeneration. PloS one 2014;9:e114569. 
93. Beste C, Konrad C, Saft C, et al. Alterations in voluntary movement execution in 
Huntington's disease are related to the dominant motor system: evidence from event-
related potentials. Exp Neurol 2009;216:148-157. 
94. Rao JA, Harrington DL, Durgerian S, et al. Disruption of response inhibition circuits in 
prodromal Huntington disease. Cortex; a journal devoted to the study of the nervous 
system and behavior 2014;58:72-85. 
95. Hot P, Rauchs G, Bertran F, et al. Changes in sleep theta rhythm are related to episodic 
memory impairment in early Alzheimer's disease. Biological psychology 2011;87:334-
339. 
96. Marshall L, Kirov R, Brade J, Molle M, Born J. Transcranial electrical currents to probe 
EEG brain rhythms and memory consolidation during sleep in humans. PloS one 
2011;6:e16905. 
97. Hobbs NZ, Pedrick AV, Say MJ, et al. The structural involvement of the cingulate cortex 
in premanifest and early Huntington's disease. Movement disorders : official journal of 
the Movement Disorder Society 2011;26:1684-1690. 
50 
 
98. Patterson RM, Bagchi BK, Test A. The prediction of Huntington's chorea; an electro-
encephalographic and genetic study. The American journal of psychiatry 1948;104:786-
797. 
99. Harvald B. On the possibility of predicting Huntington's chorea by 
electroencephalographic study. The American journal of psychiatry 1951;108:295-297. 
100. Sem-Jacobsen CW, Petersen MC, Lazarte JA, Dodge HW, Jr., Holman CB. Intracerebral 
and intracerebellar electrography in Huntington's chorea. Proceedings of the staff 
meetings Mayo Clinic 1955;30:365-370. 
101. Puca FM, Di Perri R, Margherita G. [Characteristics of the spindles during sleep in 
chorea patients]. Acta neurologica 1965;20:259-268. 
102. Chandler JH. EEG in prediction of Huntington's chorea. An eighteen year follow-up. 
Electroencephalography and clinical neurophysiology 1966;21:79-80. 
103. Scott DF, Heathfield KW, Toone B, Margerison JH. The EEG in Huntington's chorea: a 
clinical and neuropathological study. J Neurol Neurosurg Psychiatry 1972;35:97-102. 
104. Sishta SK, Troupe A, Marszalek KS, Kremer LM. Huntington's chorea: an 
electroencephalographic and psychometric study. Electroencephalography and clinical 
neurophysiology 1974;36:387-393. 
105. Iakhno NN. [Disorders of nocturnal sleep in Huntington chorea]. Zhurnal nevropatologii 
i psikhiatrii imeni SS Korsakova 1985;85:340-346. 
106. Pokrovskaia ZA, Insarova NG. [The EEG characteristics of patients with Huntington's 
chorea and their clinically healthy relatives]. Zhurnal nevropatologii i psikhiatrii imeni 
SS Korsakova 1988;88:22-26. 
107. Streletz LJ, Reyes PF, Zalewska M, Katz L, Fariello RG. Computer analysis of EEG activity 
in dementia of the Alzheimer's type and Huntington's disease. Neurobiology of aging 
1990;11:15-20. 
108. Bylsma FW, Peyser CE, Folstein SE, Folstein MF, Ross C, Brandt J. EEG power spectra in 
Huntington's disease: clinical and neuropsychological correlates. Neuropsychologia 
1994;32:137-150. 
109. de Tommaso M, De Carlo F, Difruscolo O, Massafra R, Sciruicchio V, Bellotti R. 
Detection of subclinical brain electrical activity changes in Huntington's disease using 
artificial neural networks. Clinical neurophysiology : official journal of the International 
Federation of Clinical Neurophysiology 2003;114:1237-1245. 
51 
 
110. Landau ME, Cannard KR. EEG characteristics in juvenile Huntington's disease: a case 
report and review of the literature. Epileptic disorders : international epilepsy journal 
with videotape 2003;5:145-148. 
111. Bellotti R, De Carlo F, Massafra R, de Tommaso M, Sciruicchio V. Topographic 
classification of EEG patterns in Huntington's disease. Neurology & clinical 
neurophysiology : NCN 2004;2004:37. 
112. Ullrich NJ, Riviello JJ, Jr., Darras BT, Donner EJ. Electroencephalographic correlate of 
juvenile Huntington's disease. Journal of child neurology 2004;19:541-543. 
113. van der Hiele K, Jurgens CK, Vein AA, et al. Memory activation reveals abnormal EEG in 
preclinical Huntington's disease. Mov Disord 2007;22:690-695. 
114. Hunter A, Bordelon Y, Cook I, Leuchter A. QEEG Measures in Huntington's Disease: A 
Pilot Study. PLoS Curr 2010;2:RRN1192. 
115. Painold A, Anderer P, Holl AK, et al. Comparative EEG mapping studies in Huntington's 
disease patients and controls. Journal of neural transmission 2010;117:1307-1318. 
116. Painold A, Anderer P, Holl AK, et al. EEG low-resolution brain electromagnetic 
tomography (LORETA) in Huntington's disease. J Neurol 2011;258:840-854. 
117. Ponomareva N, Klyushnikov S, Abramycheva N, et al. Alpha-theta border EEG 
abnormalities in preclinical Huntington's disease. Journal of the neurological sciences 
2014;344:114-120. 
118. Arnulf I, Nielsen J, Lohmann E, et al. Rapid eye movement sleep disturbances in 
Huntington disease. Arch Neurol-Chicago 2008;65:482-488. 
119. Arnulf I, Nielsen J, Schiefer J, et al. REM sleep disturbances in huntington disease. Sleep 
2007;30:A303-A304. 
120. Neutel D, Tchikviladze M, Charles P, et al. Nocturnal agitation in Huntington disease is 
caused by arousal-related abnormal movements rather than by rapid eye movement 
sleep behavior disorder. Sleep medicine 2015. 
121. Manconi M, Ferri R, Zucconi M, et al. Dissociation of periodic leg movements from 
arousals in restless legs syndrome. Ann Neurol 2012;71:834-844. 
 
